Brief: Vicore Pharma Establishes Safe And Well-Tolerated Dose Of C21 In Phase I Study

Vicore Pharma Holding AB

09/09/2019 09:48

Sept 9 (Reuters) - Vicore Pharma Holding AB  VICOR.ST :
    * SAID ON FRIDAY IT HAS COMPLETED PHASE I DOSE-ESCALATION
STUDY IN
VP01 PROJECT INVESTIGATING DRUG CANDIDATE C21, A FIRST IN CLASS,
ORAL, ANGIOTENSIN II TYPE 2 RECEPTOR (AT2R) AGONIST
    * STUDY ESTABLISHED THAT 200 MG DAILY HAS A GOOD SAFETY
PROFILE
AND THAT IT WAS THE MAXIMUM TOLERATED DOSE
    * THIS DOSE WILL BE USED IN PLANNED PHASE II STUDIES IN
IDIOPATHIC
PULMONARY FIBROSIS AND DIFFUSE SYSTEMIC SCLEROSIS
    * BASED ON RECEPTOR-BINDING DATA, CO HAS ALSO CONCLUDED THAT
THIS
DOSE RESULTS IN A FREE C21 PLASMA CONCENTRATION THAT IS
SUFFICIENT TO ACTIVATE AT2R
    * BOTH PHASE II STUDIES TO BE INITIATED LATER THIS YEAR

    
 Source text for Eikon:  urn:newsml:reuters.com:*:nWkrbMgr3q
 
 Further company coverage:  VICOR.ST  
   
    
    

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com))